EUVIMEDEUVIMED entdecken
VergleichsstudieBeobachtungsstudie

Real-World Outcomes in Myeloma Patients With t (11;14): A Matched Comparison Using the Canadian Myeloma Research Group National Clinical Database

Julia Varghese, Christopher P Venner, Martha Louzada, Donna Reece, Darrell White, Smriti Sharma, Jiandong Su, Michael P Chu, Victor H Jimenez-Zepeda, Arleigh McCurdy, Kevin Song, Hira Mian und 9 weitere

Clinical Lymphoma Myeloma and Leukemia · 2025

DOI: 10.1016/j.clml.2025.10.019 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Clinical Lymphoma Myeloma and Leukemia, 2025. Verfasst von Julia Varghese und 20 weiteren Autor:innen. Beteiligte Einrichtung: Vancouver General Hosptial, University of British Columbia, Vancouver, Canada. Electronic address: julia.varghese@bccancer.bc.ca. Hauptthemen laut MEDLINE: Multiple Myeloma, Translocation, Genetic, Chromosomes, Human, Pair 11, Chromosomes, Human, Pair 14. Die Arbeit nennt 22 Literaturangaben. Gefördert von: AbbVie.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: In multiple myeloma, t(11;14) confers a unique biology including a lymphoplasmacytic phenotype and an association with plasma cell leukemia. Some studies report a favourable while others a worse prognosis, compared to non-t(11;14) cases. Dependence of t(11;14) cells on the BCL2 pathway offers a potential therapeutic target. METHODS: We performed a matched comparison of real-world outcomes in patients with and without t(11;14) as a benchmark for future therapy targeting BCL2. A retrospective observational study was conducted using the Canadian Myeloma Research Group database between 2004-2022. FISH and karyotype studies were used to identify which patients carried the t(11;14) versus those who did not. Those found to harbour the t(11;14) were matched one-to-one with a non-t(11;14) cohort based on age at line 1 of therapy, gender, year of diagnosis and history of autologous stem cell transplant. RESULTS: Compared with non-t(11;14), those with t(11;14) had similar PFS during line 1 (44 (95%CI: 32-51) months vs. 44 (95%CI: 36-65) months), but shorter PFS in line 2 (18 (95% CI: 11-22) months vs. 32 (95%CI: 23-49) months) resulting in a shorter PFS2 (55 (95%CI: 45-87 months vs. 83 (95%CI: 74-115) months). CONCLUSIONS: Although not yet translating into a worse OS, this merits longer follow up. This suggests the need for optimal treatment choice and sequencing at relapse within this unique cytogenetic group. Our large, matched comparison in real-world t(11;14) myeloma serves as an important benchmark for studies looking at targeted BCL2 inhibitors in these patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Multiple MyelomaTranslocation, GeneticChromosomes, Human, Pair 11Chromosomes, Human, Pair 14HumansMaleFemaleCanadaMiddle AgedAgedRetrospective StudiesDatabases, FactualPrognosisAdultTreatment Outcome

Stichwörter der Autor:innen

BCL2 inhibitorHematologic malignancyMultiple myelomaPlasma cell dyscrasiascytogenetics

Autor:innen und Institutionen

  • Vancouver General Hosptial, University of British Columbia, Vancouver, Canada. Electronic address: julia.varghese@bccancer.bc.ca.
  • BC Cancer, Vancouver Centre, Vancouver, Canada.
  • London Regional Cancer Center, London, Ontario, Canada.
  • Princess Margaret Cancer Centre, Toronto, Canada; Canadian Myeloma Research Group, Vaughan, Ontario, Canada.
  • Queen Elizabeth II Health Sciences Centre. Dalhousie University, Halifax, Nova Scotia, Canada.
  • Canadian Myeloma Research Group, Vaughan, Ontario, Canada.

Förderung

  • AbbVie

Zitieren

APA

Varghese, J., Venner, C. P., Louzada, M., Reece, D., White, D., Sharma, S., Su, J., Chu, M. P., Jimenez-Zepeda, V. H., McCurdy, A., Song, K., Mian, H., Sebag, M., Stakiw, J., Reiman, A., Kotb, R., Aslam, M., Kaedbey, R., Bergstrom, D., …, & LeBlanc, R. (2025). Real-World Outcomes in Myeloma Patients With t (11;14): A Matched Comparison Using the Canadian Myeloma Research Group National Clinical Database. Clinical Lymphoma Myeloma and Leukemia. https://doi.org/10.1016/j.clml.2025.10.019

Vancouver

Varghese J, Venner CP, Louzada M, Reece D, White D, Sharma S, et al. Real-World Outcomes in Myeloma Patients With t (11;14): A Matched Comparison Using the Canadian Myeloma Research Group National Clinical Database. Clinical Lymphoma Myeloma and Leukemia. 2025. doi:10.1016/j.clml.2025.10.019

BibTeX
@article{Varghese2025,
  author = {Varghese, Julia and Venner, Christopher P and Louzada, Martha and Reece, Donna and White, Darrell and Sharma, Smriti and Su, Jiandong and Chu, Michael P and Jimenez-Zepeda, Victor H and McCurdy, Arleigh and Song, Kevin and Mian, Hira and Sebag, Michael and Stakiw, Julie and Reiman, Anthony and Kotb, Rami and Aslam, Muhammad and Kaedbey, Rayan and Bergstrom, Debra and Gul, Engin and LeBlanc, Richard},
  title = {Real-World Outcomes in Myeloma Patients With t (11;14): A Matched Comparison Using the Canadian Myeloma Research Group National Clinical Database},
  journal = {Clinical Lymphoma Myeloma and Leukemia},
  year = {2025},
  doi = {10.1016/j.clml.2025.10.019}
}
Kostenlos starten →